Delivery Order SPE2DR25D3301-SPE2DR26F23CC

<p>The Defense Logistics Agency issued a delivery order to Amerisourcebergen Drug Corp on February 20, 2026, for Ocrevus 300 mg/10 mL vials, with a ceiling value of $25,637.70.</p> <p>Place of performance is Conshohocken, PA. Ultimate completion date is March 13, 2026. The order carries firm fixed pricing and was not issued under a set-aside.</p>

<p>The Defense Logistics Agency issued a delivery order to Amerisourcebergen Drug Corp on February 11, 2026, for $25,637.70 ceiling value to supply Ocrevus 300 mg/10 ml vial medication.</p> <p>Place of performance is Conshohocken, PA. Ultimate completion date is March 5, 2026. The order was issued under firm fixed-price pricing with no set-aside.</p>

<p>The Defense Logistics Agency issued a delivery order to Amerisourcebergen Drug Corp on February 18, 2026, with a ceiling value of $25,637.70 for Ocrevus 300 mg/10 mL vials under firm fixed-price terms.</p> <p>Place of performance is Conshohocken, PA. The order has an ultimate completion date of March 11, 2026. No set-aside was used.</p>

<p>The Defense Logistics Agency issued a delivery order to AmerisourceBergen Drug Corp on February 26, 2026, with a ceiling value of $76,913.10 for OCREVUS 300 mg/10 mL vials.</p> <p>The order is issued under the DLA Troop Support Medical IDC held by parent company Cencora, Inc., valued at up to $999,999,999.00 through December 2026. Place of performance is Conshohocken, PA. The order carries an ultimate completion date of March 19, 2026 and is priced on a firm fixed-price basis.</p>

<p>The Defense Logistics Agency issued a delivery order to AmerisourceBergen Drug Corp on February 9, 2026, with a ceiling value of $25,637.70 for OCREVUS 300 mg/10 mL vial (10 mL).</p> <p>Place of performance is Conshohocken, PA. The order is firm fixed price with an ultimate completion date of March 3, 2026. No set-aside was used.</p>

The Defense Logistics Agency issued a delivery order to Amerisourcebergen Drug Corp on February 10, 2026, for Ocrevus 300 mg/10 ml vial 10 ml, with a ceiling value of $76,913.10. Place of performance is Conshohocken, PA. The order is issued under the DLA Troop Support Medical Indefinite Delivery Contract (SPE2DX), a global pharmaceutical support vehicle valued at $999,999,999.00 through December 2026, which enables supply of a comprehensive range of pharmaceutical products and medical supplies...

<p>The Defense Logistics Agency issued a delivery order to Amerisourcebergen Drug Corp on February 10, 2026, for $76,913.10 under a parent Indefinite Delivery Contract with the DLA Troop Support Medical (SPE2DX) for Ocrevus 300 mg/10 mL vials.</p> <p>Place of performance is Conshohocken, PA. The order is firm fixed price with an ultimate completion date of March 4, 2026. No set-aside was used.</p>

The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Ocrevus 300 mg/10 mL vials with a ceiling value of $120,192.80 and firm fixed pricing. The order is scheduled for completion by August 19, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania facility. This is an unrestricted, competitively awarded delivery order with no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to meet...

The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Ocrevus 300 mg/10 mL vials with a ceiling value of $120,192.80 and a firm fixed price structure. The order is scheduled for completion by October 14, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This non-competitive delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...

The Defense Logistics Agency awarded a $120,192.80 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Ocrevus 300 mg/10 mL vials. This is a firm fixed-price contract with an ultimate completion date of August 14, 2025, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting the contractor's demonstrated capability to meet federal pharmaceutical...